FC Advisory’s AstraZeneca AZN Stock Holding History

FC Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,680	Closed	-$220K	–	106
2024 Q4	$220K	Hold	1,680	–	–	0.07%	104
2024 Q3	$262K	Hold	1,680	–	–	0.09%	92
2024 Q2	$262K	Sell	1,680 -407	-20%	-$61.2K	0.1%	87
2024 Q1	$283K	Hold	2,087	–	–	0.1%	84
2023 Q4	$281K	Hold	2,087	–	–	0.11%	85
2023 Q3	$283K	Hold	2,087	–	–	0.12%	85
2023 Q2	$299K	Buy	+2,087	New	+$307K	0.12%	83

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

FC Advisory's AZN Position: Q1 2025 in Review

FC Advisory sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 1,680 shares — an estimated $220K sold.

FC Advisory first reported a position in AZN in Q2 2023 and held it in 7 quarters. The position peaked at $299K in Q2 2023. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

FC Advisory reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
FC Advisory sold 1,680 AstraZeneca shares in Q1 2025, an estimated $220K.
FC Advisory first reported a position in AstraZeneca in Q2 2023 and held it in 7 quarters.
FC Advisory's AstraZeneca position peaked at $299K in Q2 2023.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on FC Advisory's 13F filing for Q1 2025, filed 7 Apr 2025.